ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408860289/en/

The rotor for the new CPMAS iProbe is 0.4 mm in diameter, rotating mechanically at 160kHz (pencil for scale) (Photo: Business Wire)

The rotor for the new CPMAS iProbe is 0.4 mm in diameter, rotating mechanically at 160kHz (pencil for scale) (Photo: Business Wire)

At the 65th ENC (www.enc-conference.org), Bruker introduces a new ultra-fast CP/MAS iProbe as the latest innovation in solid-state NMR technology. Featuring a 160 kHz Magic Angle Spinning (MAS) system, it takes high-resolution MAS and proton detection on solid biological samples to the next level, enabling new scientific discoveries. The dramatically enhanced 1H-NMR resolution and enhanced T2' times make 160 kHz MAS suitable for the study of large proteins, membrane proteins and protein aggregates. Multiple 160 kHz MAS probes are available for customer demonstrations and collaborations on 700 and 800 MHz NMR spectrometers in Bruker’s applications facility in Germany. In addition, a 160 kHz MAS probe is now installed on the 1.0 GHz NMR at CNRS Lyon, where it expands the scientific capabilities of biological solid-state research.

Professor Guido Pintacuda, CNRS researcher at the Institute of Analytical Sciences in Lyon, commented: “With the new 160 kHz MAS probe we witness a leap forward in resolution, now enabling us to reveal the subtlest nuances of molecular structures and interactions. This is a bold step into the atomic-level description of biomolecules and will contribute to lift the role of NMR in disease research to the next level.”

Bruker also introduces novel technology for standard-bore (SB) DNP Probes for 600 and 800 MHz, and eventually for GHz SB magnets to allow scientists to study small molecules, proteins or materials with ultrahigh DNP-NMR sensitivity. The new SB-DNP probe technology broadens the accessibility of solid-state DNP-NMR research. Previously, wide-bore (WB) NMR magnets were required for DNP, and now the same DNP-NMR sensitivity enhancements of 50x to 200x can be achieved with more economical and widely adopted SB NMR magnets.

The new HCN SB DNP probes are available for LT-MAS below 100 Kelvin, with 1.3 mm or 0.7 mm MAS rotor diameters for high-resolution MAS even at low temperatures. Bruker is in the process of developing high-field gyrotrons for microwave frequencies of 658 GHz to 790 GHz for solid-state DNP-NMR at 1.0 and 1.2 GHz.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:

Justin Ward

Sr. Director, Investor Relations & Corporate Development

Bruker Corporation

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com

Media Contact:

Markus Ziegler

Sr. Director and Head of Group Marketing

Bruker BioSpin

T: +49 172 3733531

E: pr@bruker.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.